EDITAS MEDICINE, INC. Proceeds from Debt, Net of Issuance Costs
EDITAS MEDICINE, INC. (EDIT) reported Proceeds from Debt, Net of Issuance Costs of $1.50 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2018-03-08
- EDITAS MEDICINE, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-12-31 was $0.00.
- EDITAS MEDICINE, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-09-30 was $709.00K.
- EDITAS MEDICINE, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-06-30 was $0.00.
- EDITAS MEDICINE, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-03-31 was $791.00K.
- EDITAS MEDICINE, INC. proceeds from debt, net of issuance costs for fiscal 2015 was $1.50M, a 224.68% increase from fiscal 2014.
- EDITAS MEDICINE, INC. proceeds from debt, net of issuance costs for fiscal 2014 was $462.00K.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $709.00K derived: sum of 2 quarters · filed 2018-03-08 | $709.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.50M 10-K · filed 2018-03-08 |
| 2015-09-30 | $709.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $709.00K derived: sum of 2 quarters · filed 2016-11-09 | $1.50M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $791.00K 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $791.00K 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $462.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |